BNTX BioNTech SE
Price Chart
Executive Summary
BioNTech presented new clinical data from its late-stage lung cancer programs at the European Lung Cancer Congress 2026, highlighting promising results for pumitamig and gotistobart. Gotistobart showed a 54% reduction in risk of death in squamous NSCLC, while pumitamig and the HER3-targeted ADC BNT326/YL202 demonstrated encouraging antitumor activity and manageable safety profiles across multiple lung cancer subtypes.
Actionable Insight
Monitor progression of pivotal Phase 3 trials, especially top-line results from PRESERVE-003 and ROSETTA Lung-01/02. The 54% survival benefit with gotistobart is a strong signal; confirmatory data could drive significant valuation upside. Combination trials may unlock additional market potential.
Key Facts
- Gotistobart showed a 54% reduction in risk of death vs. standard of care in 2L+ squamous NSCLC in stage 1 of the Phase 3 PRESERVE-003 trial.
- Pumitamig demonstrated clinically meaningful survival outcomes in EGFR-mutant NSCLC and encouraging activity in ES-SCLC and NSCLC regardless of PD-L1 status.
- First clinical data for BNT326/YL202, a HER3-targeted ADC, showed antitumor activity and favorable safety in advanced NSCLC.
- Data support ongoing pivotal Phase 3 trials ROSETTA Lung-01 (ES-SCLC) and ROSETTA Lung-02 (NSCLC), and a novel combination trial of pumitamig + BNT326/YL202.
- Presentations cover 16 ongoing lung cancer trials, including four pivotal Phase 3 studies.
Financial Impact
Potential multibillion-dollar commercial opportunity if pivotal trials confirm efficacy, particularly in high-prevalence lung cancer indications.
Risk Factors
- Stage 1 data for gotistobart is non-pivotal; results may not be replicated in larger, randomized cohorts.
- All candidates are still in development with no guaranteed regulatory approval.
- Competition in lung cancer immunotherapy and ADC space is intense, with multiple established and emerging therapies.
Market Snapshot
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3261033 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
|
Jun 8, 2026
1d ago
|
6-K
| $88.08 awaiting T+5 | awaiting T+5 | — | $86.50 (−1.79%) |
|
Jun 1, 2026
8d ago
|
6-K
| $91.70 $88.08 | ▼ −3.95% | ▼ −1.20% | $86.50 (−5.67%) |
|
May 30, 2026
10d ago
|
Press Release
| $91.70 $88.08 | ▼ −3.95% | ▼ −1.20% | $86.50 (−5.67%) |
|
May 22, 2026
18d ago
|
6-K
| $92.14 $91.70 | ▼ −0.48% | ▼ −2.15% | $86.50 (−6.12%) |
|
May 22, 2026
18d ago
|
Press Release
| $92.14 $91.70 | ▼ −0.48% | ▼ −2.14% | $86.50 (−6.12%) |
|
May 15, 2026
25d ago
|
6-K
| $88.85 $92.25 | ▲ +3.83% | ▲ +2.21% | $86.50 (−2.64%) |
|
May 7, 2026
4w ago
|
6-K
| $93.02 $92.23 | ▼ −0.85% | ▼ −2.35% | $86.50 (−7.01%) |
|
May 5, 2026
5w ago
|
6-K
| $95.50 $93.66 | ▲ +1.93% | ▲ +3.91% | $86.50 (+9.42%) |
|
May 5, 2026
5w ago
|
6-K
| $95.50 $93.66 | ▼ −1.93% | ▼ −3.91% | $86.50 (−9.42%) |
|
May 5, 2026
5w ago
|
Press Release
| $95.50 $93.34 | ▼ −2.26% | ▼ −4.25% | $86.50 (−9.42%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access